Irbesartan + Hidroclorotiazida Farmoz

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbesartan + Hidroclorotiazida Farmoz, is an angiotensin II receptor blocker / thiazide diuretic presented as an oral tablet for oral use. It is used to lower high blood pressure in adult patients.

GNH USA supplies Irbesartan + Hidroclorotiazida Farmoz as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system to control elevated blood pressure.

- Hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension. - Hypertension with fluid retention: provides additional diuretic effect to manage volume overload. - Hypertension uncontrolled by monotherapy: offers combined ARB and thiazide action for patients needing two agents.

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Increased urination: more frequent need to void due to diuretic action. - Electrolyte imbalance: low potassium or sodium levels. - Fatigue: feeling unusually tired or weak. - Mild gastrointestinal upset: nausea or abdominal discomfort.

Serious or Rare Side Effects: - Severe dehydration: excessive fluid loss leading to low blood pressure. - Acute kidney injury: sudden decline in renal function. - Hyperkalemia: dangerously high potassium levels. - Angioedema: swelling of face, lips, tongue, or throat. - Severe hypotension: marked drop in blood pressure causing fainting. - Allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy, consider the following safety measures.

- Blood pressure monitoring: ensure target levels are achieved without excessive drop. - Renal function assessment: check serum creatinine and eGFR periodically. - Electrolyte surveillance: monitor potassium and sodium levels, especially in patients on other diuretics. - Hepatic impairment: use with caution in patients with liver disease. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid): - ACE inhibitors: combined use can increase risk of hyperkalemia and renal dysfunction. - Lithium: diuretic component may raise lithium concentrations, leading to toxicity. - Potassium‑sparing diuretics: additive effect on serum potassium, risking hyperkalemia. - Rifampin: enzyme induction may reduce irbesartan plasma levels. - NSAIDs: may blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives: additive blood‑pressure lowering may require dose adjustment. - CYP2C9 inhibitors (e.g., fluconazole): may increase irbesartan exposure. - Antidiabetic agents: diuretic‑induced changes in glucose may affect glycemic control. - High‑dose corticosteroids: can counteract antihypertensive effect. - Alcohol: may enhance dizziness and hypotensive effects.